Showing results (141-150 of 174) with videos related to

Sort By:
Pageof 18
Blood|January 15, 2020
External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors failsJohannes Schetelig, Henning Baldauf, Falk Heidenreich, et al.
Leukemia|December 22, 2018
Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemiaJohannes Schetelig, Liesbeth C de Wreede, Michel van Gelder, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 4, 2018
Relative Impact of HLA Matching and Non-HLA Donor Characteristics on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic SyndromeFrancis Ayuk, Dietrich W Beelen, Martin Bornhäuser, et al.
British Journal of Haematology|March 2, 2019
Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemiaNicolaus Kröger, Diderik-Jan Eikema, Linda Köster, et al.
Transplantation and Cellular Therapy|May 7, 2025
Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and SwitzerlandAlexander Denk, Matthias Alexander Fante, Silke Heidenreich, et al.
Annals of Hematology|June 15, 2017
Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantationMichael Heuser, Razif Gabdoulline, Patrick Löffeld, et al.
Annals of Hematology|November 16, 2020
Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study GroupEsther Schuler, Eva-Maria Wagner-Drouet, Salem Ajib, et al.
Bone Marrow Transplantation|July 7, 2023
Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)Eleni Gavriilaki, Ioanna Sakellari, Myriam Labopin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2017
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)Nicolaus Kröger, Simona Iacobelli, Georg-Nikolaus Franke, et al.
Blood|October 9, 2009
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationNicolaus Kröger, Ernst Holler, Guido Kobbe, et al.
Pageof 18